Variation in Weight Loss Response to GLP-1 Drugs and Rise of Telehealth Access

1-Minute Brief

Understanding why some people respond differently to GLP-1 drugs is important as telehealth expands access to these medications.

Key Facts

• Emerging research identifies 'super-responders' and non-responders to GLP-1 weight loss drugs.
• Some individuals experience significant weight loss with GLP-1 medications, while others see little or no effect.
• Telehealth providers are increasingly used by Americans to access GLP-1 weight loss medications.
• Justin Schrieber, CEO of LifeMD, stated that GLP-1 access is a primary reason for telehealth visits.
• Schrieber noted that the next area of telehealth expansion could be hormone replacement care.

What Happened

Recent research highlights varying individual responses to GLP-1 weight loss drugs, while telehealth companies report increased demand for these medications.

Why It Matters

These developments may influence how weight loss treatments are prescribed and accessed, and could affect future healthcare delivery models.

What's Next

Further research may clarify why responses to GLP-1 drugs differ, and telehealth platforms may expand offerings to include additional treatments.